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Objective. To provide guidance for the management of gout, including indications for and optimal use of urate- 
lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations.
Methods. Fifty- seven population, intervention, comparator, and outcomes questions were developed, followed by 
a systematic literature review, including network meta- analyses with ratings of the available evidence according to the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and patient input. A group 
consensus process was used to compose the final recommendations and grade their strength as strong or conditional.
Results. Forty- two recommendations (including 16 strong recommendations) were generated. Strong recommen-
dations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent 
gout flares; allopurinol as the preferred first- line ULT, including for those with moderate- to- severe chronic kidney 
disease (CKD; stage >3); using a low starting dose of allopurinol (≤100 mg/day, and lower in CKD) or febuxostat 
(<40 mg/day); and a treat- to- target management strategy with ULT dose titration guided by serial serum urate (SU) 
measurements, with an SU target of <6 mg/dl. When initiating ULT, concomitant antiinflammatory prophylaxis therapy for 
a duration of at least 3–6 months was strongly recommended. For management of gout flares, colchicine, nonsteroidal 
antiinflammatory drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly recommended.
Conclusion. Using GRADE methodology and informed by a consensus process based on evidence from the 
current literature and patient preferences, this guideline provides direction for clinicians and patients making decisions 
on the management of gout.
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are 
intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR 
considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding 
their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommen-
dations are intended to promote beneficial or desirable outcomes but cannot guarantee any  specific outcome. Guidelines and 
recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of med-
ical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions, 
and drug formularies or other third- party analyses that cite ACR guidelines should state this. These recommendations cannot 
adequately convey all uncertainties and nuances of patient care.
The American College of Rheumatology is an independent, professional, medical and scientific society that does not guaran-
tee, warrant, or endorse any commercial product or service.
This article is published simultaneously in Arthritis Care & Research.
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INTRODUCTION
Gout is the most common form of inflammatory arthritis, 
affecting ~9.2 million adults (3.9%) in the US (1). While the eti-
ology of gout is well- understood and there are effective and 
inexpensive medications to treat gout, gaps in quality of care 
persist (2–4). The 2012 American College of Rheumatology 
(ACR) Guidelines for the Management of Gout (5,6) and other 
international specialty society guidelines recommend treat- 
to- target strategies with use of urate- lowering therapy (ULT) 
(7–10). Despite these recommendations, over the past 2 de-
cades there has been no increase in ULT utilization. Adherence 
to ULT remains poor (2,11) and is the lowest adherence among 
treatments for 7 common chronic medical conditions (12). 
Complicating the efforts to improve adherence is the fact that 
the prior 2012 ACR Guidelines for the Management of Gout 
have been criticized due to low quality of evidence supporting 
treat- to- target recommendations (13,14). Since the 2012 ACR 
Guidelines for the Management of Gout were published, sev-
eral clinical trials have been conducted that provide additional 
evidence regarding the management of gout, leading the ACR 
Guidelines Subcommittee to determine that new guidelines 
were warranted.
METHODS
This guideline follows the ACR guideline development 
 process (https://www.rheum atolo gy.org/Pract ice-Quali ty/Clini cal- 
Suppo rt/Clini cal-Pract ice-Guide lines) using the Grading of 
Recom mendations Assessment, Development and Evaluation 
(GRADE) methodology to rate the certainty of evidence and 
develop recommendations (15–17), with an emphasis on develop-
ing actionable guidelines. ACR policy guided the management of 
conflicts of interest and disclosures (https://www.rheum atolo gy. 
org/Pract ice-Quali ty/Clini cal-Suppo rt/Clini cal-Pract ice-Guide 
lines/ Gout). A full description of the methods is presented in Sup-
plementary Appendix 1 (available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41247/ 
abstract).
Briefly, the Core Team, Expert Panel, and Voting Panel 
(consisting of rheumatologists, a general internist, a nephrol-
ogist, a physician assistant, and a patient representative) gen-
erated 57 population, intervention, comparator, and outcomes 
(PICO) questions to address the following: indications for ULT 
(5 questions), approaches to initiating ULT (7 questions), ongo-
ing ULT management (18 questions), gout flares (10 questions), 
and lifestyle and other medication strategies in patients with 
gout (9 questions) and in individuals with asymptomatic hyper-
uricemia (8 questions). PICO questions were posted on the 
ACR web site for public comment (October 30–November 30, 
2018) (for a list of team and panel members, see Supplemen-
tary Appendix 2, available on the Arthritis & Rheumatology web 
site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41247/ 
abstract). An in- person Patient Panel of 8 male patients with 
gout, moderated by one of the voting panel members (JAS), 
reviewed the evidence report (along with a summary and inter-
pretation by the moderator) and provided patient perspectives 
and preferences.
The Core Team prespecified outcomes as critical or 
important for each PICO question for the systematic literature 
review. Outcomes varied across PICO topic (for details, see 
Supplementary Appendix 3, at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41247/ abstract). Gout flare and serum urate 
(SU) concentration (and tophus for PICO question 1) were 
specified as critical outcomes for all PICO questions specific to 
ULT. Pain was identified as critical for PICO questions specific 
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to gout flare. Gout flare was specified as the only critical out-
come for management of lifestyle factors. All other outcomes 
were specified as important. Without standardized definitions 
for gout flare as an outcome (18), flare definitions varied by 
duration of follow- up in the various studies. Based on Patient 
Panel input, we specified that longer- term outcomes (e.g., 
24 months) would be critical, while shorter durations (e.g., 
<12 months) were considered important; it was recognized 
that very short time points (e.g., <6 months) may reflect the 
expected flares during ULT initiation.
We conducted systematic literature reviews (including 2 
network meta- analyses [NMAs]) to address each PICO ques-
tion (for search strategies and study selection process, see Sup-
plementary Appendices 4 and 5, respectively, at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41247/ abstract). The first NMA 
evaluated the impact of starting ULT versus no ULT and the rel-
ative impact of the various ULT agents (for details, see Supple-
mentary Appendix 6, available at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41247/ abstract). The second NMA evaluated 
antiinflammatory agents in gout flare management (for details, see 
Supplementary Appendix 7, available at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41247/ abstract). To accomplish this sec-
ond NMA, we grouped similar agents into nodes (e.g., acetic acid 
derivatives, profens, cyclooxygenase 2 agents, glucocorticoids, 
and interleukin- 1 [IL- 1] inhibitors).
The lowest level of evidence for the outcomes deemed crit-
ical to patients determined the certainty of evidence for each 
PICO question (15). For PICO questions specific to ULT, and 
on the basis of input from 1) the Patient Panel; 2) prior focus 
group work citing the importance of SU, gout flare, and tophi 
to patients (19); and 3) prior guidance from the GRADE work-
ing group  (20), we made the following decisions. Where there 
was moderate or high certainty of evidence demonstrating 
improvement in any 1 of these 3 outcomes, we deemed this 
sufficient evidence to support a strong recommendation. The 
certainty of evidence from the other 2 outcomes was then des-
ignated as important but not  critical to support the recommen-
dation. The certainty of the evidence for each recommendation 
is presented in Tables  1–8, and the certainty of evidence for 
each outcome within each PICO question is in the full evidence 
report (see Supplementary Appendix 8, available on the Arthri-
tis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41247/ abstract).
Additionally, we report results using the more conservative 
rating of the evidence using the lowest level of evidence for 
any of the critical outcomes. Applying these more conservative 
rules, the summary certainty of evidence decreased (in com-
parison to the reported results) for some of the ULT recom-
mendation statements, which would result in a lower strength 
of recommendation for 2 recommendations (PICO question 2: 
ULT indication for patients with erosions, and PICO question 
27: switching to pegloticase for ULT failure). The details are 
available in the evidence report (Supplementary Appendix 8). 
Medication costs (not part of the systematic literature review), 
reported as average wholesale pricing as sourced from Lexi-
comp on August 23, 2019, were provided to the Voting Panel, 
as cost of treatment was included as part of the evaluation of 
risks and benefits of treatment medications (see Supplemen-
tary Appendix 9, available on the Arthritis & Rheumatology web 
site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41247/ 
abstract).
PICO questions were drafted into recommendation state-
ments and were sent to the Voting Panel with the evidence report 
prior to round 1 voting. At a face- to- face meeting, the Voting Panel 
again reviewed draft recommendations, a summary of the vot-
ing results from round 1, the evidence report, and a summary of 
Patient Panel statements (1 patient from the Patient Panel [JES] 
and the Patient Panel moderator [JAS] attended the Voting Panel 
and were available to answer questions about the Patient Panel 
statements). To become a recommendation (for or against) in 
this guideline, at least 70% consensus of the Voting Panel was 
required.
The strength of each recommendation was rated as strong 
or conditional. Strong recommendations reflect decisions sup-
ported by moderate or high certainty of evidence where the 
benefits consistently outweigh the risks, and, with only rare 
exceptions, an informed patient and his or her provider would be 
expected to reach the same decision. Conditional recommen-
dations reflect scenarios for which the benefits and risks may 
be more closely balanced and/or only low certainty of evidence 
or no data are available.
Recommendations in this guideline apply to patients with 
gout, except for a single recommendation regarding the use of 
ULT in individuals with asymptomatic hyperuricemia, which is 
defined as an SU concentration of ≥6.8 mg/dl with no prior gout 
flares or subcutaneous tophi. Patients with evidence of mono-
sodium urate monohydrate (MSU) deposition on advanced imag-
ing may still be considered asymptomatic if they have not had a 
prior gout flare or subcutaneous tophi.
These guidelines do not directly address the impact of gout 
or hyperuricemia on other comorbidities, such as cardiovascular 
disease (CVD), hypertension, urolithiasis, or chronic kidney dis-
ease (CKD). As we developed these guidelines for use by provid-
ers practicing in the US, we considered pharmacologic therapies 
available in the US, with select exceptions. Although lesinurad 
was withdrawn from the US market by the manufacturer during 
the course of guideline development, it remains Food and Drug 
Administration (FDA) approved, and we therefore considered 
the data in relation to relevant PICO questions. To facilitate the 2 
NMAs, we also considered medications not available in the US to 
permit comparisons with other available medications in the net-
work analysis.
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RESULTS/RECOMMENDATIONS
Indications for pharmacologic ULT
Initiating ULT is strongly recommended for 
gout patients with any of the following: ≥1 subcuta-
neous tophi; evidence of radiographic damage (any 
modality) attributable to gout; OR frequent gout 
flares, with frequent being defined as ≥2 annually.
From the ULT NMA (see Supplementary Appendix 6, 
available at http://onlin elibr ary.wiley.com/doi/10.1002/art.41247/ 
abstract) and randomized clinical trials (RCTs) of pegloticase 
(21–23) and lesinurad (24), there was high certainty of evidence 
regarding the efficacy of ULT in reducing flare frequency (23–26), 
tophi (21,23), and SU concentrations (23–26). While many Patient 
Panel participants reported that they were initially hesitant to start 
ULT, after experiencing improved control of inflammatory symp-
toms and tophi, they became strong advocates for its earlier insti-
tution  (for all indications for pharmacologic ULT, see Table 1 and 
Supplementary Figure  1, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.41247/abstract).
Initiating ULT is conditionally recommended 
for patients who have previously experienced >1 
flare but have infrequent flares (<2/year).
For patients with less frequent flares and no tophi, the poten-
tial clinical benefit of ULT would be lower than the ULT benefit for 
patients with more burdensome gout. In a single study (moder-
ate certainty of evidence), patients with ≤2 previous flares (and 
no more than 1 gout flare in the preceding year) randomized to 
receive febuxostat (versus placebo) were less likely to experience 
a subsequent flare (30% versus 41%; P < 0.05) (27).
Specific characteristics for patients with infrequent flares 
(e.g., SU concentration >9 mg/dl, CKD, CVD) that might influence 
the risk- benefit assessment were considered, but due to insuffi-
cient data for these subgroups, the Voting Panel did not find that 
these conditions warranted stronger ULT recommendations spe-
cific to these subgroups.
Initiating ULT is conditionally recommended 
against in patients with gout experiencing their 
first gout flare.
However, initiating ULT is conditionally rec-
ommended for patients with experiencing their 
first flare when comorbid moderate- to- severe 
CKD (stage  ≥3), SU concentration >9 mg/dl, or 
urolithiasis is present.
While conditionally recommending against ULT initiation fol-
lowing the first gout flare in a patient with “uncomplicated” gout, 
the Voting Panel considered Patient Panel input and recognized 
that there may be patients who would prefer (or benefit from) ULT, 
underscoring the need for shared decision- making. As noted 
above, data from the RCT of patients with ≤2 previous flares (and 
no more than 1 gout flare in the preceding year) supported the ben-
efit of ULT for reduction of SU concentration and gout flare risk (27). 
For patients with moderate- to- severe CKD (e.g., stage >3), there 
is a higher likelihood of gout progression and development of clini-
cal tophi (28–30). Furthermore, treatment options for gout flare are 
limited in this population, and there may be added benefit of using 
ULT to prevent progression of renal disease (31). Similarly, patients 
with markedly elevated SU concentrations (>9 mg/dl) are more 
likely to experience gout progression (26,32). For patients with a 
history of urolithiasis, allopurinol and febuxostat provide benefit, as 
both medications lower 24- hour urinary uric acid excretion more 
than placebo (33). Among patients with calcium oxalate stones 
and hyperuricosuria, allopurinol (300 mg/day) is superior to pla-
cebo in reducing the 3- year incidence of stone- related events (34).






For patients with 1 or more subcutaneous tophi, we strongly recommend initiating ULT over no ULT. 1 High
For patients with radiographic damage (any modality) attributable to gout, we strongly recommend 
initiating ULT over no ULT.
2 Moderate
For patients with frequent gout flares (>2/year), we strongly recommend initiating ULT over no ULT. 3 High
For patients who have previously experienced >1 flare but have infrequent flares (<2/year), we conditionally 
recommend initiating ULT over no ULT.
4 Moderate
For patients experiencing their first flare, we conditionally recommend against initiating ULT over no ULT, 
with the following exceptions.
5 Moderate
For patients experiencing their first flare and CKD stage >3, SU >9 mg/dl, or urolithiasis, we conditionally 
recommend initiating ULT.
5 Very low
For patients with asymptomatic hyperuricemia (SU >6.8 mg/dl with no prior gout flares or subcutaneous 
tophi), we conditionally recommend against initiating any pharmacologic ULT (allopurinol, febuxostat, 
probenecid) over initiation of pharmacologic ULT.
57 High†
* PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; SU = serum urate. 
† There is randomized clinical trial data to support the benefit that ULT lowers the proportion of patients who develop incident gout. However, 
based on the attributable risk, 24 patients would need to be treated for 3 years to prevent a single (incident) gout flare leading to the 
recommendation against initiating ULT in this patient group. 
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Initiating ULT is conditionally recommended 
against in patients with asymptomatic hyperuri-
cemia.
For patients with asymptomatic hyperuricemia, RCTs 
(designed to study CVD outcomes) demonstrated significant 
reduction in incident gout flares over 3 years. However, the 
development of incident gout was low for both ULT and pla-
cebo arms (<1% versus 5%) (35,36). In other words, 24 patients 
would need to be treated with ULT for 3 years to prevent a 
single (incident) gout flare. From observational studies, among 
patients with asymptomatic hyperuricemia with SU concentra-
tions of >9 mg/dl, only 20% went on to develop gout within 5 
years (32). The Voting Panel felt that, on average, for the major-
ity of patients with asymptomatic hyperuricemia (including those 
with comorbid CKD, CVD, urolithiasis, or hypertension), the 
benefits of ULT would not outweigh potential treatment costs 
or risks for the large number of patients unlikely to progress 
to gout. This is also the case for patients with asymptomatic 
hyperuricemia with MSU crystal deposition as noted on imaging 
tests such as ultrasound or dual- energy computed tomography.
Recommendations for choice of initial ULT for 
patients with gout
Treatment with allopurinol as the preferred 
first- line agent, over all other ULTs, is strongly 
recommended for all patients, including those 
with moderate- to- severe CKD (stage ≥3).
The Voting Panel strongly recommended allopurinol as the 
preferred first- line agent given its efficacy when dosed  appropriately 
(often required doses >300 mg/day [37] up to the maximum FDA- 
approved dose of 800 mg/day [38]), tolerability, safety, and lower 
cost. Using a lower starting dose mitigates safety issues specific 
to allopurinol hypersensitivity syndrome (AHS) (39,40). The Vot-
ing Panel indicated that an optimal trial of oral medication would 
be appropriate prior to pegloticase due to cost differences and 
potential adverse effects of the latter medication (for recommen-
dations for choice of initial ULT, see Table 2 and Supplementary 
Figure  2, available at http://onlinelibrary.wiley.com/doi/10.1002/
art.41247/abstract).
The choice of either allopurinol or febuxostat 
over probenecid is strongly recommended for pa-
tients with moderate- to- severe CKD (stage ≥3).
The choice of pegloticase as a first- line thera-
py is strongly recommended against.
Starting treatment with low- dose allopuri-
nol (≤100 mg/day and lower in patients with CKD 
[stage ≥3]) and febuxostat (≤40 mg/day) with sub-
sequent dose titration over starting at a higher 
dose is strongly recommended.
Starting treatment with low- dose probenecid 
(500 mg once to twice daily) with subsequent dose 
titration over starting at a higher dose is condi-
tionally recommended.
A lower starting dose of any ULT reduces the risk of flare asso-
ciated with initiation (41). The Patient Panel voiced a strong pref-
erence for safer ULT prescribing regimens through lower starting 
doses with subsequent dose escalation, even if such regimens 
required more blood draws and provider visits, over alternate 
regimens (e.g., starting with higher doses) that might incur more 
risk. Even lower initial allopurinol doses (e.g., ≤50 mg/day) 






For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first- line 
agent for all patients, including in those with CKD stage >3.
10 Moderate
We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage >3.
For allopurinol and febuxostat, we strongly recommend starting at a low dose with subsequent dose titration 
to target over starting at a higher dose (e.g., <100 mg/day [and lower in patients with CKD] for allopurinol or 
<40 mg/day for febuxostat). 
7 Moderate
For probenecid, we conditionally recommend starting at a low dose (500 mg once or twice daily) with dose 
titration over starting at a higher dose.
We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, 
prednisone/prednisolone) over no antiinflammatory prophylaxis. 
The choice of specific antiinflammatory prophylaxis should be based upon patient factors.
9 Moderate
We strongly recommend continuing prophylaxis for 3–6 months rather than <3 months, with ongoing 
evaluation and continued prophylaxis as needed if the patient continues to experience flares.
9 Moderate
When the decision is made that ULT is indicated while the patient is experiencing a gout flare, we 
conditionally recommend starting ULT during the gout flare over starting ULT after the gout flare has 
resolved.
6 Moderate
We strongly recommend against pegloticase as first- line therapy. 10 Moderate†
* PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; NSAIDs = nonsteroidal antiinflammatory drugs. 
† Moderate evidence is in support of the efficacy of pegloticase, but due to cost, safety concerns, and favorable benefit- to- harm ratios of other 
untried treatment options, the recommendation is against using pegloticase as first- line agent. 
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should be considered in patients with CKD. While higher  starting 
doses and CKD are associated with risk of AHS (39), patients 
with CKD may still require dose titration above 300 mg/day 
to achieve the SU target (42,43). A population pharmacokinetic– 
pharmacodynamics study showed that larger body size and 
diuretic use indicated the need for higher allopurinol doses to 
achieve greater urate reduction. Worse renal function only had 
a modest negative impact on urate reduction (44). Other studies 
have demonstrated that allopurinol dose escalation can be done 
safely in this population (40,45).
Administering concomitant antiinflammatory 
prophylaxis therapy (e.g., colchicine, nonsteroi-
dal antiinflammatory drugs [NSAIDs], prednisone/
prednisolone) over no antiinflammatory prophy-
laxis therapy is strongly recommended.
Based on 8 RCTs (41,46–52) and 2 observational studies 
(53,54), there is moderate certainty of evidence to support the 
strong recommendations to use antiinflammatory prophylaxis 
therapy when initiating ULT. Continuation of prophylaxis for at 
least 3–6 months after ULT initiation was recommended because 
shorter durations were associated with flares upon cessation of 
prophylaxis (55,56). After cessation, monitoring for flare activity 
and continuation of antiinflammatory treatment as needed if the 
patient continues to experience flares was recommended.
Continuing concomitant antiinflammatory 
prophylaxis therapy for 3–6 months over <3 
months, with ongoing evaluation and continued 
prophylaxis as needed if the patient continues to 
experience gout flares, is strongly recommended.
Timing of ULT initiation
When the decision is made that ULT is indicat-
ed while the patient is experiencing a gout flare, 
starting ULT during the gout flare over starting 
ULT after the gout flare has resolved is condition-
ally recommended.
Starting ULT during a flare has conceptual benefits, including 
the time efficiency offered by initiating therapy during the concur-
rent flare visit rather than risking the patient not returning for ULT 
initiation. Furthermore, input from the Patient Panel emphasized 
that patients are likely to be highly motivated to take ULT due to 
the symptoms related to the current flare. However, concerns 
about starting ULT during a flare include potential extension or 
worsening of a flare, as well as the possibility of information over-
load for patients, which may lead to conflating flare management 
and long- term ULT. Two small RCTs (57,58) and an observational 
study (59) support the hypothesis that starting ULT during a flare 
does not significantly extend flare duration or severity. Input 
from the Patient Panel, citing their own ability to simultaneously 
process information related to flare treatment and ULT initiation 
together, along with their preference to start on a treatment path 
sooner to prevent future flares, influenced the final recommen-
dation. As with all conditional recommendations, there may be 
patient factors or preferences that would reasonably support the 
alternative of delaying ULT initiation until the flare has resolved.
A treat- to- target management strategy that 
includes ULT dose titration and subsequent dos-
ing guided by serial SU measurements to achieve a 
target SU, over a fixed- dose ULT strategy, is strong-
ly recommended for all patients receiving ULT.
Achieving and maintaining an SU target of <6 
mg/dl over the use of no target is strongly recom-
mended for all patients receiving ULT.
We recommend using a treat- to- target management strategy 
to optimize patient outcomes by achieving and maintaining an SU 
target of <6 mg/dl rather than using a fixed- dose strategy (Table 3 
and Supplementary Figure 2, available at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41247/ abstract). There is moderate- and 
high- quality evidence supporting these 2 recommendations. In an 
RCT from the UK (43), patients randomized to a nurse- led, treat- 
to- target protocol demonstrated greater ULT adherence, lower SU 
concentrations, reduction in tophi, and a lower proportion of fre-
quent (≥2) gout flares at 24 months, compared with patients ran-
domized to general practitioner–led usual care (an approach more 
often characterized by a fixed- dose strategy when ULT is adminis-
tered). Two separate pharmacist- led interventions in the US, both 
incorporating treat- to- target strategies, were superior to usual 
care in terms of treatment adherence, SU outcomes, and higher 
allopurinol dosing (60,61). Additional studies provide support for 
ULT dose escalation to achieve target SU levels, including dose 
titration of allopurinol in patients with CKD (40,43). While a specific 
dose titration schedule is left to provider and patient to individual-
ize based on patient comorbidities and preferences, ULT titration 
should occur over a reasonable time frame (e.g., weeks to months, 
not years) to prevent “treatment inertia” (62). In contrast to the 2012 
ACR Guidelines for the Management of Gout, due to lack of sup-
porting evidence for additional specific thresholds, we do not define 
further thresholds for patients warranting more intensive ULT.
Delivery of an augmented protocol of ULT dose 
management by nonphysician providers to op-
timize the treat- to- target strategy that includes 
patient education, shared decision- making, and 
treat- to- target protocol is conditionally recom-
mended for all patients receiving ULT.
Based on recent nurse- (43) and pharmacist- led (60,61) inter-
ventions, the Voting Panel supported the benefit of an  augmented 
delivery- of- care using patient education and shared decision- 
making through implementation of a treat- to- target protocol over 
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usual care. However, the panel recognized that these resources may 
not be available in all health care settings, and that the key is for the 
treating provider (who could be the treating physician) to educate 
the patient and implement a treat- to- target protocol.
Duration of ULT
Continuing ULT indefinitely over stopping ULT 
is conditionally recommended.
For patients in clinical remission taking ULT (e.g., no flares 
for ≥1 year and no tophi [63]), the Voting Panel considered 
ULT cessation or tapering. In a single case series where ULT 
was withheld in patients in clinical remission with years of well- 
controlled SU concentrations prior to cessation, only 13% 
of patients (27 of 211) whose SU concentration remained at 
<7 mg/dl while not receiving ULT had no flares during a 5- year 
follow- up period. Furthermore, patients with higher SU con-
centrations after withholding therapy had more frequent flares 
with greater likelihood of flares associated with higher SU lev-
els (37). The Patient Panel voiced concerns about a return or 
worsening of gout symptoms, tophi, or joint damage with ULT 
cessation. If therapy is well- tolerated and not burdensome, the 
Patient Panel expressed a preference to continue treatment.
Recommendations for patients receiving ULT 
medications
Allopurinol
Testing for the HLA–B*5801 allele prior to 
starting allopurinol is conditionally recommend-
ed for patients of Southeast Asian descent (e.g., 
Han Chinese, Korean, Thai) and for African Ameri-
can patients, over not testing for the HLA–B*5801 
allele.
Universal testing for the HLA–B*5801 allele pri-
or to starting allopurinol is conditionally re comm -
en ded against in patients of other ethnic or racial 
background over testing for the HLA–B*5801 allele.
As noted above, starting allopurinol in daily 
doses of ≤100 mg (and lower doses in patients 
with CKD) is strongly recommended over starting 
at a higher dose.
The HLA–B*5801 allele is associated with a markedly ele-
vated risk for AHS (64,65). The prevalence of HLA–B*5801 
is highest among persons of Han Chinese, Korean, and Thai 






For all patients taking ULT, we strongly recommend a treat- to- target strategy of ULT dose management that 
includes dose titration and subsequent dosing guided by serial SU values to achieve an SU target over a 
fixed, standard- dose ULT strategy.
13 Moderate
For all patients taking ULT, we strongly recommend continuing ULT to achieve and maintain an SU target of <6 
mg/dl over no target.
14 High
For all patients taking ULT, we conditionally recommend delivery of an augmented protocol of ULT dose 
management by nonphysician providers to optimize the treat- to- target strategy that includes patient 
education, shared decision- making, and treat- to- target protocol.
8 Moderate
We conditionally recommend continuing ULT indefinitely over stopping ULT. 19 Very low
* PICO = population, intervention, comparator, outcomes; SU = serum urate. 







We conditionally recommend testing HLA–B*5801 prior to starting allopurinol for patients of Southeast Asian 
descent (e.g., Han Chinese, Korean, Thai) and African American patients, who have a higher prevalence of 
HLA–B*5801.
12 Very low
We conditionally recommend against HLA–B*5801 testing in all others.
For patients with a prior allergic response to allopurinol who cannot be treated with other oral ULT, we 
conditionally recommend using allopurinol desensitization.
23 Very low
Febuxostat
For patients with gout taking febuxostat with a history of CVD or a new CV event, we conditionally recommend 
switching to an alternative ULT agent if available and consistent with other recommendations in this guideline.
22 Moderate
Uricosurics
For patients considered for, or taking uricosuric treatment, prior to starting any uricosuric treatment, we 
conditionally recommend against checking urinary uric acid over checking urinary uric acid.
28 Very low
For patients taking uricosuric treatment, we conditionally recommend against alkalinizing urine. 29 Very low
* PICO = population, intervention, comparator, outcomes; CVD = cardiovascular disease. 
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descent (7.4%) (66), lower among African Americans (3.8%), and 
even lower among whites and Hispanics (0.7% each) (66). Test-
ing for this allele among Asians and African American patients 
was reported to be cost- effective (incremental cost- effectiveness 
ratios <$109,000 per quality- adjusted life years) (67). Asian and 
African American patients taking allopurinol both have a 3- fold 
increased risk of AHS compared with white patients taking allo-
purinol (68) (for recommendations for ULT medications, see 
Table 4 and Supplementary Figure 3, available at http://onlineli-
brary.wiley.com/doi/10.1002/art.41247/abstract).
Allopurinol desensitization is conditionally 
recommended for patients with a prior allergic 
response to allopurinol who cannot be treated 
with other oral ULT agents.
The level of evidence supporting this recommendation was 
very low (69,70). The Voting Panel recognized that desensitiza-
tion protocols (69,70) are not commonly used, with the majority 
of currently practicing rheumatologists having limited experience 
in these protocols.
Febuxostat
Switching to an alternative oral ULT agent, 
if available and consistent with other recommen-
dations in this guideline, is conditionally recomm-
ended for patients taking febuxostat with a 
history of CVD or a new CVD- related event.
At the Voting Panel meeting, there was much discussion 
about the data, Patient Panel input, and interest to provide 
recommendations consistent with the FDA black box warning 
for febuxostat (71). The Voting Panel considered data from the 
CARES RCT (72) and 2 observational studies (73,74). In the 
FDA- mandated CARES trial of febuxostat versus allopurinol (72), 
there was no difference between the 2 arms in the primary com-
posite CVD end point. Febuxostat, however, was associated 
with a higher risk of CVD- related death and all- cause mortal-
ity (driven by CVD deaths) compared with allopurinol, but there 
was no association with the other 3 secondary CVD outcomes 
(nonfatal myocardial infarction, nonfatal stroke, or urgent revas-
cularization for unstable angina). Interpretation of these results 
is complicated by a high dropout rate with a majority of deaths 
occurring after ULT discontinuation (72). Moreover, the lack of an 
untreated control group means the absolute CVD risk related to 
febuxostat is unknown. A large observational study (recruitment 
not selected for CVD) did not show an increased risk of CVD 
or all- cause mortality associated with febuxostat initiation com-
pared with allopurinol using methods to address confounding by 
indication (73). Another study using a managed care database 
demonstrated lower risk of any major CVD event among febux-
ostat initiators than allopurinol initiators, though confounding by 
indication may not have been adequately addressed (74). The 
Patient Panel representative stated members would be willing 
to accept “some” incremental CVD risk as long as the treatment 
adequately controlled their gout. Thus, as for many such deci-
sions with conditional recommendations, providers and patients 
should engage in shared decision- making when considering 
febuxostat for patients at high risk for CVD.
Uricosurics
Checking urinary uric acid is conditionally rec-
ommend against for patients considered for or re-
ceiving uricosuric treatment.
Alkalinizing the urine is conditionally recom-
mended against for patients receiving uricosuric 
treatment.
A single observational study demonstrated that higher levels 
of 24- hour urinary uric acid and higher levels of undissociated uri-
nary uric acid were associated with urolithiasis (75). However, the 
Voting Panel indicated that the challenges with 24- hour urine col-
lection or nomogram- based testing, which can both be affected 
by diet, negate the utility of such testing in light of a very low level 
of evidence.
We found no evidence to support a recommendation of 
checking urinary uric acid level for patients receiving uricosuric 
treatment or for alkalinizing the urine. The Voting Panel supported 
standard best practice that patients with known renal calculi 
or moderate- to- severe CKD (stage >3) should not be treated with 
uricosurics. For patients who are treated with uricosurics, patients 
should receive counseling about adequate hydration, but they 
need not be prescribed alkalinizing agents given the lack of evi-
dence for efficacy.
As use of uricosurics remains infrequent, we did not for-
mally vote on indications for uricosuric medications. However, 
we concur with the 2012 ACR Guidelines for the Management 
of Gout that add- on therapy to partially responsive xanthine oxi-
dase inhibitor (XOI) treatment can result in improved SU control 
(24,25,76).
When to consider changing ULT strategy
Switching to a second XOI over adding a uri-
cosuric agent is conditionally recommended for 
patients taking their first XOI, who have per-
sistently high SU concentrations (>6 mg/dl) de-
spite maximum- tolerated or FDA- indicated XOI 
dose, and who have continued frequent gout 
flares (>2 flares/year) OR who have nonresolving 
subcutaneous tophi.
Several lesinurad studies demonstrated the benefit of add-
ing a uricosuric medication to XOI treatment (25,76). However, 
we found no studies directly addressing the choice in the above 
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PICO question, resulting in the conditional recommendation to 
switch to a second XOI after the first XOI failure (for recommenda-
tions for consideration of changing ULT strategy, see Table 5 and 
Supplementary Figure 2, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.41247/abstract).
Switching to pegloticase over continuing cur-
rent ULT is strongly recommended for patients 
with gout for whom XOI treatment, uricosurics, 
and other interventions have failed to achieve 
the SU target, and who continue to have frequent 
gout flares (≥2 flares/year) OR who have nonre-
solving subcutaneous tophi.
Switching to pegloticase over continuing cur-
rent ULT is strongly recommended against for 
patients with gout for whom XOI treatment, uri-
cosurics, and other interventions have failed to 
achieve the SU target, but who have infrequent 
gout flares (<2 flares/year) AND no tophi.
In clinical trials, patients with 3 or more self- reported gout 
flares during the previous 18 months, ≥1 tophi, and gouty 
arthropathy, defined clinically or radiographically as joint damage 
due to gout, were randomly assigned to pegloticase treatment. 
Patients additionally had contraindication to treatment with 
allo purinol or history of treatment failure to normalize uric acid 
despite ≥3 months of treatment with the maximum medically 
appropriate allopurinol dose (determined by the treating physi-
cian). For these patients with frequent gout flares or nonresolv-
ing subcutaneous tophi, clinical trials demonstrated improved 
SU concentrations, low frequency of flares (77), reduction in 
tophi (21), and improved quality of life (22) among those receiv-
ing pegloticase. However, these outcomes come with high 
costs, twice- monthly infusions, and the potential for serious 
allergic reactions. For patients with infrequent gout flares and 
no tophi, we would expect a similar benefit in SU reduction. For 
patients with only infrequent flares, the magnitude of benefit 
would be substantially smaller than for patients with frequent 
flares, and there would be no benefit in reduction of tophi when 
no tophi are present. The harms and costs of administering 
pegloticase would likely be similar in patients with mild ver-
sus severe disease, resulting in limited benefit and appreciable 
harm along with very high costs, leading the panel to conclude 
that the costs and harms clearly outweigh the benefits. This 
conclusion, along with strong Patient Panel statements about 
not wanting to receive twice- monthly infusions to prevent 
infrequent gout flares, resulted in the strong recommendation 
against using pegloticase for patients with mild disease.
The above scenarios represent extremes of gout clinical 
severity resulting in strong “for” and “against” recommendations. 
The Voting Panel considered intermediary scenarios, but given the 
potential variability, the panel opted to simply defer to provider 
judgment balanced with patient preferences, regarding the optimal 
treatment strategy for individuals not described above. To clarify, 
as outlined above, there is a strong recommendation to follow a 
treat- to- target management strategy for all patients receiving ULT. 
However, the recommendation for treat- to- target strategy is not 
absolute and not meant to be pursued at “any cost.” Even strong 
recommendations require sound clinical judgment to balance the 
potential clinical benefits and harms (including costs) of medical 
decisions (78).
Gout flare management
Using colchicine, NSAIDs, or glucocorticoids (oral, 
intraarticular, or intramuscular) as appropriate first- 
line therapy for gout flares over IL- 1 inhibitors or 
adrenocorticotropic hormone (ACTH) is strongly rec-
ommended for patients experiencing a gout flare.
Given similar efficacy and a lower risk of ad-
verse effects, low- dose colchicine over high- dose 
colchicine is strongly recommended when colchi-
cine is the chosen agent.






For patients with gout taking their first XOI monotherapy at maximum- tolerated or FDA- indicated dose who 
are not at SU target and/or have continued frequent gout flares or nonresolving subcutaneous tophi, we 
conditionally recommend switching the first XOI to an alternate XOI agent over adding a uricosuric agent.
24 Very low
For patients with gout where XOI, uricosurics, and other interventions have failed to achieve SU target and 
who have frequent gout flares or nonresolving subcutaneous tophi, we strongly recommend switching to 
pegloticase over continuing current ULT.†
27 Moderate
For patients with gout for whom XOI, uricosurics, and other interventions have failed to achieve serum urate 
target and who have infrequent gout flares (<2 flares/year) and no tophi, we strongly recommend against 
switching to pegloticase over continuing current ULT.‡
27 Moderate
* PICO = population, intervention, comparator, outcomes; XOI = xanthine oxidase inhibitor; FDA = Food and Drug Administration. 
† There is moderate certainty of evidence about the efficacy of the benefits, harms, and high certainty about the costs of pegloticase. For patients 
with high disease activity, the magnitude of potential benefits outweighs the harms and costs of the drug. 
‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. 
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Using topical ice as an adjuvant treatment 
over no adjuvant treatment is conditionally rec-
ommended for patients experiencing a gout flare.
Using an IL- 1 inhibitor over no therapy (beyond 
supportive/analgesic treatment) is conditional-
ly recommended for patients experiencing a gout 
flare for whom the above antiinflammatory thera-
pies are either ineffective, poorly tolerated, or con-
traindicated.
Treatment with glucocorticoids (intramus-
cular, intravenous, or intraarticular) over IL- 1 
inhibitors or ACTH is strongly recommended for 
patients who are unable to take oral medications.
The Voting Panel’s recommendation of colchicine, NSAIDs, 
or glucocorticoids as preferred first- line therapies was based 
on substantial trial data demonstrating efficacy, relative low cost 
(versus IL- 1 inhibitors and ACTH), and tolerability of these agents 
in flare management, particularly when administered early after 
symptom onset. Appropriate dosing and duration should be 
guided by the severity of the flare. For colchicine specifically, the 
FDA- approved dosing should be followed (1.2 mg immediately 
followed by 0.6 mg an hour later, with ongoing antiinflammatory 
therapy until the flare resolves). Based on similar efficacy between 
agents demonstrated in the NMA (79–88), the Voting Panel did 
not further prioritize between the first- line agents, noting that 
treatment selection should be driven by patient factors (e.g., 
comorbidity, access, past experience) as part of shared decision- 
making. Likewise, parenteral glucocorticoids were favored over 
alternative agents when oral dosing is not possible. In patients 
experiencing an inadequate response to an initial agent, the Voting 
Panel cited insufficient evidence to make specific recommenda-
tions regarding subsequent antiinflammatory agents to use. If a 
patient is unable to tolerate or has contraindications to any of the 
other  conventional alternatives, the Voting Panel conditionally rec-
ommended the use of IL- 1 inhibitors (84,88–90), recognizing con-
cerns over patient access due to cost. Noting limited supporting 
data (91), the Voting Panel recommended the use of topical ice as 
an adjuvant therapy for flares.
Underscoring the importance of optimal flare management, 
the Patient Panel emphasized its preference for early interven-
tion given the challenges of engaging a provider in timely man-
ner, including an at- home “medication- in- pocket” strategy for 
patients who are able to identify the early signs of flare onset. In 
the absence of “rapid” access to an effective oral medication, the 
Patient Panel also indicated its preference for an injectable therapy 
in appropriate circumstances to achieve pain relief as quickly as 
possible (for all recommendations for gout flare managment, see 
Table  6 and Supplementary Figure  4, available at http://online 
library.wiley.com/doi/10.1002/art.41247/abstract).
Management of lifestyle factors
Limiting alcohol intake is conditionally rec-
ommended for patients with gout, regardless of 
disease activity.
Limiting purine intake is conditionally recom-
mended for patients with gout, regardless of dis-
ease activity.
Limiting high- fructose corn syrup intake is 
conditionally recommended for patients with 
gout, regardless of disease activity.
Using a weight loss program (no specific 
 program endorsed) is conditionally recommended 
for those patients with gout who are overweight/
obese, regardless of disease activity.






For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or 
glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first- line therapy for gout flares over 
IL- 1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on 
patient factors and preferences).
When colchicine is the chosen agent, we strongly recommend low- dose colchicine over high- dose colchicine 
given its similar efficacy and fewer adverse effects.
32 High†
For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or 
contraindicated, we conditionally recommend using IL- 1 inhibition over no therapy (beyond supportive/
analgesic treatment).
33 Moderate
For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or 
intraarticular) over IL- 1 inhibitors or ACTH.
32 High†
For patients experiencing a gout flare, we conditionally recommend using topical ice as an adjuvant treatment 
over no adjuvant treatment.
31 Low
* PICO = population, intervention, comparator, outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IL- 1 = interleukin- 1; ACTH = 
adrenocorticotropic hormone; NPO = nothing by mouth (nulla per os). 
† High quality of evidence from network meta- analyses supporting canakinumab, which has superior mean pain score reduction and mean day- 2 
joint tenderness reduction. However, the Voting Panel raised concern that the comparator was weak (triamcinolone 40 mg) and that cost issues 
significantly favor other agents. 
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Adding vitamin C supplementation is condi-
tionally recommended against for patients with 
gout, regardless of disease activity.
The Voting Panel discussed data demonstrating the impor-
tant genetic contributions to the development and severity of 
hyperuricemia and gout (92,93) and informally recommended 
that providers be mindful when soliciting information regarding 
the dietary habits of patients and ensure that discussions regard-
ing dietary recommendations are not misinterpreted as “patient- 
blaming,” as patients frequently feel stigmatized when discussing 
gout with their providers (94). Dietary modifications likely yield only 
small changes in SU concentration, but dietary factors may serve 
as triggers for flares, and patients frequently seek advice on die-
tary management (for recommendations for management of life-
style factors, see Table 7 and Supplementary Figure 5, available 
at http://onlinelibrary.wiley.com/doi/10.1002/art.41247/abstract).
Alcohol. SU levels among patients who limited or 
abstained from alcohol were 1.6 mg/dl lower compared 
with patients who did not do so (95,96). Results from a re-
cent diet and genetics meta- analysis that was noted above 
(92) demonstrated that the impact of diet or individual 
food items on SU concentration was small. As an exam-
ple, a unit of beer raised SU concentrations by 0.16 mg/dl. 
The effects of a healthy diet, Mediterranean diet, or Dietary Ap-
proaches to Stop Hypertension (DASH) diet were even smaller 
(92).
In a case- crossover study, consuming >1–2 alcoholic 
beverage servings in the prior 24 hours was associated with 
a 40% higher risk of gout flare than periods without alcohol 
consumption, with a dose- response relationship (97). A small 
cohort study demonstrated that despite receiving ULT, heavy 
drinkers (≥30 units of alcohol/week) were more likely to con-
tinue having gout flares compared with those who do did not 
drink heavily (95).
Low purine diet. From the same case- crossover study 
noted above, there was a dose- response relationship between 
increasing purine intake and risk of gout flare (98). However, a 
small RCT (n = 29, with all participants receiving ULT with SU 
at target at the start of trial) using an educational intervention 
focused on low purine intake did not demonstrate lower SU 
concentrations  compared with usual diet, despite significant im-
provements in patient dietary knowledge (99).
High- fructose corn syrup. The ingestion of 1 gm of 
fructose/kg of body weight increases SU concentration by 1–2 
mg/dl within 2 hours of ingestion (100). In the National Health 
and Nutrition Examination Survey, artificially sweetened carbonat-
ed beverage consumption was associated with higher SU levels 
(101). In the Nurses’ Health Study, greater consumption of high- 
fructose corn syrup was associated with higher risk of incident 
gout (102). However, there were no data focused on patients with 
existing gout.
Weight loss. The Voting Panel considered the impact of 
weight loss and specific dietary programs (including the DASH 
diet [103]). Due to small sample sizes, studies of patients with-
out gout (or not defined), and risk of bias assessments, the cer-
tainty of the evidence was rated as very low for both SU and 
flares. Several studies and a systematic literature review (104) 
addressed weight loss approaches either directly (96,105) or 
indirectly (e.g., bariatric surgery [106,107], or dietary advice 
[108]). In a small cohort (n = 11) of obese patients, a mean 
weight loss of 5 kg resulted in a mean SU lowering of 1.1 mg/
dl (96). In a large cohort study, obesity was associated with a 
higher risk of incident gout, but not recurrent gout flares (105). 
However, changes in body mass index (BMI) over time were 
associated with the risk of recurrent gout flare. An increase in 
BMI of >5% was associated with 60% higher odds of recur-
rent flare, and a decrease in BMI of >5% was associated with 
40% lower odds of recurrent flare compared with those without 
weight change (–3.5% < BMI < 3.5%) (105). A small study of 12 
patients undergoing bariatric surgery (mean 34.3 kg weight loss 
over 12 months) demonstrated a mean SU reduction of 2.0 mg/
dl (106). Likewise, gout patients losing weight through bariatric 
surgery or diet experienced reduced flare frequency (108), al-
though  patients undergoing  bariatric surgery may actually have 






For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake. 41 Low
For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake. 42 Low
For patients with gout, regardless of disease activity, we conditionally recommend limiting high- fructose 
corn syrup.
43 Very low
For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight 
loss.
46 Very low
For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C 
supplementation.
48 Low
* PICO = population, intervention, comparator, outcomes. 
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a transient increase in flares risk during the first postoperative 
month (106).
Other dietary recommendations. The Voting Pan-
el reviewed the data for cherries/cherry extract and dairy protein. 
The certainty of evidence drawn mainly from observational stud-
ies was low or very low, precluding specific recommendations on 
these topics. The Voting Panel reached consensus that data on 
vitamin C were insufficient to support continued recommendation 
for its use in patients with gout. Two small RCTs (n = 29 and n = 
40) showed clinically insignificant changes in SU concentrations 
for patients with gout taking vitamin C (99,109).
Management of concurrent medications
Switching hydrochlorothiazide to an alternate 
antihypertensive when feasible is conditionally 
recommended for patients with gout, regardless 
of disease activity.
Choosing losartan preferentially as an antihy-
pertensive agent when feasible is conditionally 
recommended for patients with gout, regardless 
of disease activity.
Stopping low- dose aspirin (for patients taking 
this medication for appropriate indications) is 
conditionally recommended against for patients 
with gout, regardless of disease activity.
Adding or switching cholesterol- lowering 
agents to fenofibrate is conditionally recom-
mended against for patients with gout, regardless 
of disease activity.
Medications noted above are known to have effects on SU 
concentrations (110). The Voting Panel made recommendations 
specific to hydrochlorothiazide and losartan (111) in clinical sce-
narios where such changes are feasible. Switching, stopping, or 
adding a medication should only be considered when the poten-
tial SU concentration/gout benefits exceed the potential risks or 
harms of the medication change.
Recognizing that there are few practical alternatives to low- 
dose aspirin, the Voting Panel specifically recommended against 
its cessation as a means of SU reduction when a patient is taking 
it for an appropriate indication. Likewise, the Voting Panel spe-
cifically recommended against adding or switching cholesterol- 
lowering agents (e.g., statins, bile acid sequestrants, nicotinic acid 
agents, etc.) to fenofibrate despite its urate- lowering effects (112), 
as the risks, including side effects of the medication, were felt to 
outweigh potential benefits. Although likely to render only modest 
urate- lowering effects, switching from an angiotensin- converting 
enzyme inhibitor to losartan carries a risk that seems to be suf-
ficiently low in most patients to merit this change when feasible 
(for all recommendations for management of concurrent medica-
tions, see Table 8 and Supplementary Figure 5, available at http://
onlinelibrary.wiley.com/doi/10.1002/art.41247/abstract).
DISCUSSION
This guideline reinforces many of the prior 2012 ACR Guide-
lines for the Management of Gout recommendations with updated 
literature and GRADE methodology, including incorporation of 
patient preferences and consideration of costs. The Voting Panel 
endorsed 42 recommendations overall, including 16 strong rec-
ommendations focused on ULT management (indications [n = 3], 
initiation [n = 6], titration and treat- to- target approach [n = 2], 
approaches following ULT failure [n = 2]), and flare management 
(n = 3).
Data from more recent RCTs comparing treat- to- target pro-
tocols versus usual care (43,61) provide the basis for the strong 
recommendation to use a treat- to- target strategy with ULT that 
includes a plan to achieve and maintain an SU target of <6 mg/dl 
to optimize patient outcomes. Findings from the evidence report 
resonated with the Patient Panel who concurred that their own 
SU levels correlated with related symptoms and changes in tophi. 
Patients on this panel articulated that SU assessments reinforced 
the importance of treatment adherence.
These guidelines reinforce the strategy of starting with low- 
dose ULT and titrating up to achieve the SU target. This strat-
egy mitigates the risk of treatment- related adverse effects (e.g., 
hypersensitivity) as well as flare risk accompanying ULT initiation 
(39,41). Lacking data on optimal titration regimens, the Voting 
Panel indicated that titration should be individualized, based on 
available provider resources (e.g., staff for augmented delivery of 
care), patient preferences, the timing of ambulatory encounters, 






For patients with gout, regardless of disease activity, we conditionally recommend 
switching hydrochlorothiazide to an alternate antihypertensive when feasible. 
47 Very low
We conditionally recommend choosing losartan preferentially as an antihypertensive when feasible. 47 Very low
We conditionally recommend against stopping low- dose aspirin (in those who are taking this medication for 
appropriate indications).
47 Very low
We conditionally recommend against adding or switching to fenofibrate. 47 Very low
* PICO = population, intervention, comparator, outcomes. 
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and antiinflammatory treatments. As described above, ULT titra-
tion should occur over weeks to months, not years. The 2012 
ACR Guidelines for the Management of Gout recommended titra-
tion every 2–5 weeks (5). As noted in the ACR Clinical Quality Mea-
sures for Gout, SU concentrations should be checked after each 
dose titration (113). To limit the risk of ULT- related flares, these 
guidelines reinforce prior recommendations to use concurrent 
antiinflammatory prophylaxis for 3–6 months’ duration, a shorter 
duration than advocated for in prior recommendations, but one 
that should be extended in the setting of frequent ongoing flares.
Breaking from prior ACR and European League Against 
Rheumatism (EULAR) guidelines, this guideline does not specify 
SU thresholds beyond <6 mg/dl for patient subsets with more 
severe disease (e.g., those with tophi). This guideline is not 
intended to contradict or dispute prior recommendations. There 
is ample evidence that lower SU levels hasten the resolution of 
tophi (23,114) and are associated with less frequent gout flares 
(26,114), suggesting that lower SU thresholds may be preferable 
for patients with more burdensome gout. However, in contrast to 
a treatment strategy using an SU target of <6 mg/dl as studied in 
clinical trials (43), there are no trial data to support lower specific 
thresholds for such patients.
In contrast to the 2012 ACR Guidelines for the Manage-
ment of Gout (which did not consider treatment costs), this doc-
ument firmly places allopurinol as the preferred first- line ULT for 
all patients, including those with CKD, due to the respective cost 
of each medication and potential CVD safety concerns that have 
recently emerged with febuxostat (72).
Under GRADE methodology, recommendations in these 
guidelines are supported by higher quality studies than the 2012 
ACR Guidelines for the Management of Gout. This resulted in 
a more focused, less proscriptive document. Where certainty of 
data is less than moderate or high, conditional recommenda-
tions made herein are meant to highlight those decisions that 
would benefit from a shared patient- provider decision- making 
process. This would include areas such as diet, lifestyle, or con-
comitant medications that might affect SU levels, and for which 
the Patient Panel requested guidance. The Voting Panel aimed 
to provide guidance without implying any “patient- blaming” for 
the manifestations of gout given its strong genetic determinants.
Indications for ULT are expanded from the 2012 ACR Guide-
lines for the Management of Gout, but consistent with the 2016 
update of the EULAR gout recommendations (10), to include 
individuals with evidence of radiographic damage attributable to 
gout (using any modality, regardless of subcutaneous tophi or flare 
frequency). This strong recommendation recognizes the various 
ways in which gout may present, and that joint damage is reflective 
of an active biologic process. Also added were conditional recom-
mendations (which would warrant provider- patient shared medi-
cal decision- making discussion) for ULT use in patients with either 
infrequent flares (<2 flares/year) or a first flare with marked hyper-
uricemia (SU >9 mg/dl). Similar to the 2012 ACR Guidelines for the 
Management of Gout, the Voting Panel advocated a “medication- 
in- pocket” strategy for gout flare management, which the Patient 
Panel reinforced as a preferred approach.
This updated guideline effort also identifies several areas 
that inform a research agenda for gout management. While 
data support an active treat- to- target strategy, a question 
remains as to what may be the optimal SU threshold for 
patients with more severe disease, in addition to questions 
about threshold values in specific populations of gout patients. 
Gout has differential impact on patients by sex, race, or by 
presence of other comorbidities. This guideline is limited in 
commenting on specific groups of gout patients, as more 
studies of specific patient cohorts are needed in order to make 
differential recommendations. Additional studies are needed 
to determine the safety of prolonged and profound treatment- 
related hypouricemia (e.g., SU ≤3 mg/dl), an important knowl-
edge gap given that epidemiologic studies have suggested 
an inverse association of SU concentration with select neu-
rodegenerative disorders (115). While there are associations 
between SU and other comorbid conditions such as hyper-
tension, CVD, and CKD (116), the benefit (or risk) of ULT in the 
absence of gout has yet to be established (117).
Gout has been characterized as a “curable disease” (118). 
As data continue to emerge supporting best practices in manage-
ment, implementation of these recommendations will ideally lead 
to improved quality of care for patients with gout.
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